Exicure, Inc. (XCUR)

NASDAQ: XCUR · IEX Real-Time Price · USD
0.610
+0.017 (2.92%)
At close: Feb 23, 2024, 4:00 PM
0.600
-0.010 (-1.64%)
After-hours: Feb 23, 2024, 6:14 PM EST
2.92%
Market Cap 5.28M
Revenue (ttm) 23.79M
Net Income (ttm) 3.07M
Shares Out 8.65M
EPS (ttm) 1.68
PE Ratio 0.36
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 129,244
Open 0.593
Previous Close 0.593
Day's Range 0.590 - 0.720
52-Week Range 0.365 - 1.500
Beta 1.19
Analysts n/a
Price Target n/a
Earnings Date Mar 25, 2024

About XCUR

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 7
Stock Exchange NASDAQ
Ticker Symbol XCUR
Full Company Profile

Financial Performance

Financial Statements

News

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company ...

20 days ago - Business Wire

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023...

3 months ago - Business Wire

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.

6 months ago - Business Wire

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.

7 months ago - Business Wire

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update.

8 months ago - Business Wire

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonuclei...

9 months ago - Business Wire

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

CHICAGO--(BUSINESS WIRE)--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.

10 months ago - Business Wire

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc., reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.

11 months ago - Business Wire

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

CHICAGO--(BUSINESS WIRE)--Exicure today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.

1 year ago - Business Wire

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated tar...

1 year ago - Business Wire

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated ta...

1 year ago - Business Wire

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

CHICAGO--(BUSINESS WIRE)--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.

1 year ago - Business Wire

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

CHICAGO--(BUSINESS WIRE)--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.

1 year ago - Business Wire

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.

1 year ago - Business Wire

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...

1 year ago - Business Wire

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...

1 year ago - Business Wire

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...

1 year ago - Business Wire

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

CHICAGO--(BUSINESS WIRE)--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.

1 year ago - Business Wire

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.

1 year ago - Business Wire

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

CHICAGO--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...

1 year ago - Business Wire

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

1 year ago - Business Wire

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

Exicure Inc (NASDAQ: XCUR) has reported year-end cash, cash equivalents, and short-term investments of $48.3 million that will fund its current operations into Q4 of 2022. The Company said that it exp...

2 years ago - Benzinga

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial ...

2 years ago - Business Wire

Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?

San Diego, California--(Newsfile Corp. - February 17, 2022) - Johnson Fistel, LLP is investigating potential claims on behalf of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR) against certa...

2 years ago - Newsfile Corp

Exicure Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile C...

2 years ago - Newsfile Corp